PoC Test R&D Complicated By Emergency Consent Provisions – Genzyme Rep
This article was originally published in The Gray Sheet
Executive Summary
FDA emergency research regulations requiring a therapeutic window to obtain informed consent may slow down development of rapid diagnostics for stroke and heart attack, according to Genzyme VP-Regulatory Affairs Robert Yocher